Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Scandium-43 is an emerging PET radiometal that was produced by α-particle bombardment on natural CaCO target via Ca (α,p) Sc and Ca (α,n) Ti→Sc reactions using K-130 cyclotron at VECC. A robust radiochemical procedure based on selective precipitation of Sc as Sc(OH) was developed for separation of the radioisotope from the irradiated target. The overall yield of the separation process was >85% and it was obtained in a form suitable for preparation of target specific radiopharmaceuticals for PET imaging of cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apradiso.2023.110921 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multidimensional in silico evaluation of fluorine-18 radiopharmaceuticals: integrating pharmacokinetics, ADMET, and clustering for diagnostic stratification.
J Comput Aided Mol Des
September 2025
Department of Medical Physics and Biomedical Nanotechnologies, V.N. Karazin Kharkiv National University, 4 Svobody Sq., Kharkiv, 61022, Ukraine.
Fluorine-18-labeled radiopharmaceuticals are central to PET-based oncology imaging, yet comparative evaluations of their mechanistic behavior and diagnostic potential remain fragmented. In this study, we present a multidimensional in silico framework integrating pharmacokinetic modeling, structural ADMET prediction, and unsupervised clustering to systematically evaluate five widely used F-labeled PET radiopharmaceuticals: [F]FDG, [F]FET, [F]DOPA, [F]FMISO, and [F]FLT. Each radiopharmaceutical was simulated using a harmonized three-compartment model in COPASI to capture uptake dynamics under both normal and pathological conditions.
View Article and Find Full Text PDFImplementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access.
Semin Nucl Med
August 2025
Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa; Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa; Department of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, South Africa. Electro
Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted radiotherapy in a single, personalized approach. Over the past decade, the field has gained substantial momentum, with several radiopharmaceuticals now incorporated into clinical practice, most notably for neuroendocrine tumors and prostate cancer. The pipeline of novel agents continues to grow, offering promising therapeutic options for patients with cancers resistant to conventional therapies.
View Article and Find Full Text PDFA Targeted Radiotheranostic Agent for Glioblastoma: [Cu]Cu-NOTA-TP-c(RGDfK).
Brain Sci
August 2025
Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Glioblastoma multiforme (GBM) remains one of the most aggressive and treatment-resistant brain tumors, with poor prognosis and limited therapeutic options. : Integrin αβ, a cell surface receptor overexpressed in GBM, specifically binds to cyclic arginine-glycine-aspartate-D-phenylalanine-lysine (c(RGDfK)) motif, making it a valuable target for tumor-specific delivery and PET imaging. This study explores a novel radiotheranostic agent, [Cu]Cu-NOTA-TP-c(RGDfK), which combines the imaging and therapeutic capabilities of copper-64 (Cu) and the cytotoxic activity of a terpyridine-platinum (TP) complex, conjugated to c(RGDfK).
View Article and Find Full Text PDF[Sc]Sc-CHX-A″-DTPA-RCCB6: A PET Tracer for Imaging CD70 Expression Across Latency Types of Burkitt Lymphoma.
J Nucl Med
August 2025
Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin;
CD70 is a promising target for advancing the diagnosis and treatment of Burkitt lymphoma (BL). A Sc-labeled single-domain antibody fragment tracer, [Sc]Sc-CHX-A″-DTPA-RCCB6, was developed and assessed for its potential in CD70-targeted immuno-PET imaging using BL models. RCCB6 single-domain antibody was conjugated with CHX-A″-DTPA and radiolabeled with Sc.
View Article and Find Full Text PDFMonte Carlo study of the eye lens exposure of medical staff administering Sc-47 and Cu-67 labelled radiopharmaceuticals.
Phys Med
August 2025
Department of Medical Physics, AUSL Reggio Emilia (RE), via Amendola 2, 42122, Italy.
Purpose: In the last decades, new technologies and new radiopharmaceuticals for diagnosis and therapy have continuously grown, and that growth was accompanied by an increasing use in clinical practice, but, as with any other application involving radiation, the extent to which they may contribute to increasing the radiation dose to the operator must be studied. For that reason, EURADOS (European Radiation Dosimetry Group) decided to evaluate the exposure of medical staff in nuclear medicine to new possible radiopharmaceuticals labelled with Sc-47 and Cu-67.
Methodology: Modified ICRP voxel model were employed to determine the exposure of the eye lens and of the thyroid of operators administrating radiopharmaceuticals in a typical Peptide Receptor Radionuclide Therapy scenario.